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Abstract: 
Recent developments in optical molecular imaging allow for real-time identification of 
morphological and biochemical changes in tissue associated with gastrointestinal neoplasia.  This 
review summarizes widefield and high resolution imaging modalities currently in pre-clinical 
and clinical evaluation for the detection of colorectal cancer and esophageal cancer.  Widefield 
techniques discussed include high definition white light endoscopy, narrow band imaging, 
autofluoresence imaging, and chromoendoscopy; high resolution techniques discussed include 
probe-based confocal laser endomicroscopy, high-resolution microendoscopy, and optical 
coherence tomography.   Finally, new approaches to enhance image contrast using vital dyes and 
molecular-specific targeted contrast agents are evaluated. 
Introduction 
Gastrointestinal (GI) neoplasia is a leading contributor to global cancer mortality and 
morbidity [1].   Early detection of cancers of the gastro-intestinal tract significantly improves 
patient outcomes; however, current clinical practice often fails to detect these cancers until they 
are at an advanced stage when treatment is more invasive, more expensive, and less successful 
[1-3]1.  This review highlights the potential of new optical molecular imaging techniques to 
improve early detection of GI cancers, with a focus on two important sites: colorectal cancer and 
esophageal cancer.    
Colorectal cancer is a leading cause of cancer related deaths worldwide [1].  In the United 
States, it is the third most common cancer amongst men and women and accounts for 9% of all 
cancer deaths.  The 5-year survival rate increases from 64% to 90% when detection occurs 
during the early stages of development [4].  Since the prognosis of late stage colorectal cancer is 
so poor, it is important to accurately screen patients.  Colorectal cancer can be prevented by the 
removal of colorectal polyps before they progress to cancer. Although colonoscopy is highly 
sensitive and has the potential to prevent approximately 65% of colorectal cancers from 
developing, some polyps can still be missed, prompting the need for increasingly sensitive 
imaging techniques [5,6].      
The incidence of esophageal adenocarcinoma (EAC) is rapidly increasing worldwide.  
Approximately 24,000 cases of EAC are diagnosed each year in the United States.  The 5-year 
survival rate for late stage EAC is only 2.8%, whereas for local-staged tumors it is 49.3% [4].  
With earlier diagnosis, however, the 5-year survival rate for stage 0 EAC exceeds 95% [7].  
Barrett’s esophagus (BE) is a benign treatable condition of the esophagus that arises due to acid 
reflux.  Individuals with BE are at higher risk of developing precancerous lesions, which can 
progress to EAC.  Because of this increased risk, it is recommended that individuals with BE 
undergo routine endoscopic examination at regular intervals to facilitate detection and treatment 
of precancers and early cancers.  However, using standard, white light endoscopy it can be 
difficult to identify early neoplastic lesions.  Thus, routine endoscopic surveillance of BE also 
includes random four-quadrant biopsies taken every 1-2 cm along the Barrett’s segment [3,4].  
Studies have shown that random four-quadrant biopsies can have miss rates up to 48% [8,9].  
Furthermore, random four-quadrant biopsies taken every 2 cm can miss up to half of the cancers 
found when a protocol of 1 cm is used [10].   
Thus, there is an important need for new approaches that can improve the ability to 
identify early neoplastic lesions in the GI tract.  This need has prompted the development of new 
optical imaging modalities to improve recognition and enable in vivo characterization of 
suspicious lesions in the GI tract.  These approaches leverage both endogenous optical contrast 
as well as the use of contrast agents targeted against biomarkers that are associated with early 
neoplasia.  This review summarizes recent advances in optical molecular imaging techniques to 
recognize early neoplastic disease in the GI tract.  The paper first discusses new approaches that 
are in clinical evaluation; these approaches are based primarily on endogenous optical contrast 
and/or the use of vital dyes to enhance image contrast.  The paper then describes approaches in 
development and preclinical evaluation, including the development of molecular-specific 
targeted contrast agents.  
Clinical Studies 
Several complementary widefield and high resolution imaging techniques are being 
evaluated to assist in the endoscopic detection and characterization of early neoplasia in the GI 
tract.  Wide-field imaging modalities are designed to survey large areas of tissue, while high 
resolution imaging is limited to smaller fields of view but can achieve subcellular resolution.  A 
variety of studies have been conducted to evaluate the performance of widefield imaging and 
high resolution imaging techniques in the clinical setting.   An overview of these emerging 
technologies and the results of several recent clinical studies are provided in this section. 
Widefield Imaging 
With the development of high definition white light endoscopy (HD-WLE), the spatial 
resolution of standard white light endoscopy (WLE) has been drastically improved [11].  Narrow 
band imaging (NBI) is a complementary widefield technique that can assist in tissue 
characterization by enhancing the visibility of vasculature in the tissue via illumination with 
narrow bands of blue and green light, selected to match spectral regions with increased 
hemoglobin absorbance [12].  Neoplastic changes are often accompanied by an increase in 
microvasculature density.  Hemoglobin is known to absorb wavelengths between 400-500 nm.  
The visualization of microvasculature can therefore be enhanced by using optical filters to only 
pass two bands of illumination.  Generally, green (530-550 nm) and blue (390-445 nm) 
wavelengths are used. The absorption of blue and green light by hemoglobin causes the 
vasculature to appear much darker than surrounding tissue without the need of a contrast agent.   
Several clinical studies have been conducted to assess the effectiveness of NBI for 
detecting early neoplasia, but they have produced varying results.  Some recent studies 
performed with the Olympus GIFQ240 have shown advantages of NBI as compared to HD-WLE 
[13,14].  In a single center study involving 75 cites on 21 patients with BE, Singh et al. 
compared diagnoses made with NBI and HD-WLE to histology results and found that the NBI 
diagnosis agreed with the histology results more often than HD-WLE (88.9% vs. 71.9%) [13].  
Muto et al. conducted a multicenter randomized trial comparing the detection rates of NBI and 
HD-WLE for early superficial esophageal squamous cell carcinoma (ESCC), a condition 
unrelated to BE.  Of the 121 patients with histologically confirmed superficial ESCC, 63 patients 
with a total of 107 lesions were evaluated primarily with NBI followed by a secondary 
evaluation with HD-WLE, and the remaining 58 patients with a total of 105 lesions were 
evaluated primarily with HD-WLE followed by NBI.  In the first group NBI alone detected 104 
of the 107 lesions, while in the second group HD-WLE alone detected only 58 of the 105 lesions, 
yielding sensitivities of 97% and 55%, respectively.  However, when the results of the secondary 
evaluations were considered, HD-WLE did not find any additional lesions in the first group, but 
the addition of NBI with HD-WLE in the second group increased the sensitivity to 95% [14].   
However, other recent studies performed with the Olympus H180 have indicated that the 
performance of NBI and HD-WLE are similar [15,16].  Sharma et al. investigated the detection 
rate of intestinal metaplasia (IM) and neoplasia, the detection rate of neoplasia specifically, and 
the number of overall biopsies performed in 123 patients with BE for evaluations with NBI and 
HD-WLE.  Half of the patients were randomly selected to receive HD-WLE examination, where 
biopsies of visible lesions were taken followed by random four quadrant biopsies for every 2 cm 
of the BE segment.  The remaining patients received NBI examination, where biopsies were first 
taken of visible lesions, followed by targeted biopsies of areas detected by NBI.  All patients 
returned within 3-8 weeks to receive the alternative procedure from a different endoscopist.  
Both modalities identified 104 of 113 patients with intestinal metaplasia, demonstrating a 
detection rate of 92%.  Patients that were missed by the first procedure were found to have IM in 
the subsequent procedure.  NBI resulted in a total of 267 biopsies, while the standard 2 cm 
protocol resulted in 321 biopsies with HD-WLE.  Histology was used to classify each biopsy as 
no IM, IM, low-grade dysplasia (LGD), high-grade dysplasia (HGD), or EAC.  NBI did detect 
significantly more areas for any form of neoplasia, but when the analysis was limited to areas 
with HGD or EAC, there was no statistical difference between the two modalities.  However, 
NBI did require fewer biopsies per patient (3.6 vs. 7.6, respectively) [16].  Pasha et al. analyzed 
a series of randomized controlled trials to determine the detection rate and miss rate for colon 
polyps and adenomas by NBI and HD-WLE.  They evaluated six studies for the detection of 
adenomas and the detection of patients with polyps, four studies for the detection of patients with 
adenomas, and five studies for the detection of adenomas <10 mm, flat adenomas, and the 
number of flat adenomas per patient, and found no statistical difference in the performance of 
NBI and HD-WLE.  They also found no statistical difference in the polyp miss rate (three 
studies) or adenoma miss rate (three studies) between the two modalities [17].   
Another widefield imaging technique, autofluorescence imaging (AFI), uses one 
wavelength of light to stimulate endogenous fluorophores in the tissue, triggering the emission of 
fluorescent light at longer wavelengths.  The emitted light can be imaged on a charge-coupled 
device (CCD) using an emission filter to block scattered excitation light.  Neoplasia is associated 
with changes in endogenous fluorescence; neoplastic epithelial cells are associated with 
increased fluorescence from mitochondrial co-factors NAD(P)H and FAD and collagen in the 
stroma near neoplastic lesions shows reduced fluorescence  [18].  Like NBI, AFI does not 
require the application of a contrast agent.  While studies have shown that AFI results in an 
increase in sensitivity for detection of early neoplasia in BE as compared to WLE, it has also 
demonstrated high false positive rates [19-23].  False positive rates as high as 40% have been 
reported using AFI for detection of early neoplasia in BE [19].  The high false positive rate of 
AFI is attributed to inflammation, which is also associated with loss of auto-fluorescence [20, 
21] .  Studies have indicated that when NBI is used in combination with AFI the false positive 
rate can be reduced, but in these studies NBI has misidentified high grade dysplasia as normal 
[19, 22]. 
A recent study by Curvers et al. compared the performance of the endoscopic trimodal 
imaging (ETMI) system (Olympus GIFQ260FZ, available in Europe and Asia) to standard WLE.  
The ETMI system can perform HD-WLE, AFI, and NBI.  The study compared the detection rate 
of early neoplasia in Barrett’s esophagus for each modality in 99 patients with low-grade 
intraepithelial neoplasia.  All of the patients underwent two consecutive procedures with the 
ETMI (consisting of HD-WLE followed by AFI and NBI) and standard WLE in random order, 
each performed by two separate endoscopists with no particular expertise in BE or advanced 
imaging techniques.  The endoscopist performing the second procedure was blinded to the results 
of the first procedure.  Targeted biopsies were first taken from areas identified as suspicious, and 
the imaging modality that detected each suspicious area was noted.  Four quadrant random 
biopsies every 2 cm were then taken.  In Figure 1A through 1C, images from a patient with no 
lesions are shown for HD-WLE, AFI, and WLE, respectively.  In Figure 1D and 1E, an early 
carcinoma is observed with HD-WLE and WLE, respectively.  An additional lesion is visible via 
AFI, indicated by the yellow arrow in Figure 1G, which was not visible in the HD-WLE image 
of Figure 1F.  The NBI image of Figure 1H shows suspicious abnormal blood vessels in the area 
of the lesion.  This study found no significant difference in the overall (targeted + random) 
detection of dysplasia by ETMI versus standard WLE.  There was no significant difference in the 
targeted detection of dysplastic lesions (low-grade intraepithelial neoplasia, high-grade 
intraepithelial neoplasia, or carcinoma) with HD-WLE detecting dysplasia in 23 patients as 
compared to 21 patients with standard WLE.  However, the addition of AFI led to the detection 
of an additional 22 dysplastic lesions in 14 patients, increasing the number of detected patients 
from 21 to 35.   NBI was associated with a decrease in the false positive rate, but was also 
associated with a reduction in sensitivity.  Of the 24 patients with high grade intraepithelial 
neoplasia or carcinoma, random biopsies led to detection in only 6 patients evaluated with ETMI 
and 7 patients evaluated with standard WLE [23].   
Figure  1.  Top  row: widefield  images  acquired  from 
endoscopically normal esophagus with  (A) HD‐WLE, 
(B) AFI, and (C) standard WLE.  Middle row: widefield 
images  acquired  from  an  early  carcinoma with  (D) 
HD‐WLE and (E) WLE; the carcinoma is located at the 
12 o’clock position. Bottom row: (F) and (G) show an 
AFI  positive  lesion  (arrow)  containing  high‐grade 
intra‐epithelial  neoplasia  that was  not  seen  during 
HD‐WLE.  (H)  NBI  showed  irregular  mucosal  and 
vascular  patterns  and  abnormal  blood  vessels 
suspicious  for  dysplasia.  (Curvers  W,  van  Vilsteren 
FG,  Baak  LC,  et  al.    Endoscopic  trimodal  imaging 
versus  standard  video  endoscopy  for  detection  of 
early Barrett’s neoplasia: a multicenter randomized, 
crossover  study  in  general  practice.    Gastrointest 
Endosc 2011;73:195‐203; with permission) 
 
 
Other widefield imaging techniques have exploited contrast agents to enhance the 
visibility of neoplastic changes.  Chromoendoscopy involves the use of stains, such as Lugol’s 
iodine, to differentiate the areas of stratified squamous epithelium from areas of metaplasia 
associated with BE [12].  Ishimura et al. investigated the use of NBI and chromoendoscopy to 
assist in the detection of squamous islands for the diagnosis of short-segment BE, which is 
characterized by segments of metaplasia that are less than 2–3 cm in length.  The number of 
identifiable squamous islands was documented first with HD-WLE, followed by NBI, and finally 
with chromoendoscopy, as shown in Figure 2A through 2C, respectively.  Of the 100 patients 
evaluated in the study, squamous islands were visible in 48 of the patients using HD-WLE, 71 
patients with NBI, and 75 patients with chromoendoscopy.  NBI exhibited a detection rate of 
94.7% as compared to chromoendoscopy.  By contrast, HD-WLE demonstrated a detection rate 
of 64% when compared to chromoendoscopy.  The mean number of detected squamous islands 
for HD-WLE, NBI, and chromoendoscopy was 0.55 ± 0.06, 1.02 ± 0.09, and 1.76 ± 0.18, 
respectively.  While chromoendoscopy remains the most accurate way of visibly identifying 
squamous islands, NBI yielded comparable results without the risk of side effects from the use of 
Lugol’s iodine [24].   
 
Figure 2. Endoscopic identification of the squamous islands in short‐segment Barrett’s esophagus with 
three different modalities: white light endoscopy (a), narrow band imaging endoscopy (b), and iodine 
chromoendoscopy (c). (Ishimura N, Amano Y, Uno G, et al.  Endoscopic characteristics of short‐segment 
Barrett’s esophagus, focusing on squamous islands and mucosal folds.  J Gastroenterol Hepatol 2012;27:82‐
7; with permission) 
 
 
 
High Resolution Imaging 
High resolution imaging modalities can achieve sub-cellular resolution, albeit with small 
fields of view.  This approach, which can provide an image similar to what is seen in histology, 
is often termed “optical biopsy”.  High resolution imaging is especially useful for targeting 
biopsies by providing a live image of the cellular architecture before the biopsy is taken [25-28].  
There are a number of different high resolution imaging modalities currently being used in vivo; 
these include confocal laser endomicroscopy (CLE) [24-27] and high resolution microendoscopy 
[34, 35]. 
The main advantage of CLE over conventional microscopy is the use of a spatial filter to 
reject out-of-focus light, capturing preferentially from tissue located at the focal point of the 
imaging system.  Because only the light from the focal plane of the system is captured, images 
can also be acquired at different depths.  The typical resolution achievable with CLE is on the 
order of 1-2 microns with a field of view of approximately 500-700 μm2.  CLE can be used either 
to image reflected light, or to image fluorescent light, typically with exogenous fluorescent 
contrast agents, such as fluorescein, acraflavine, and proflavine [24-26,29,31,32] 
In practice, there are several variations of CLE that are used to acquire high resolution 
images.  A commonly used type of CLE is probe-based confocal laser endomicroscopy (pCLE).  
pCLE employs a coherent optical fiber bundle composed of over 10,000 optical fibers as the 
conduit between the light source and the tissue.  Since only the remitted light originating from 
the focal point will propagate back through the fiber bundle efficiently, each individual fiber acts 
as a spatial filter to reject the out-of-focus light, providing optical sectioning.  By scanning the 
excitation light across the entire bundle, a high resolution image can be formed.  Commercial 
systems from companies such as Mauna 
Kea Technologies (CellVizio) and 
Pentax are available and have been used 
in several studies [25-27,30,31].   Figure 
3 shows representative fluorescence 
images of  4 distinct sites of normal 
squamous epithelium in the esophagus, 
Barrett’s esophagus, high grade 
dysplasia, and  squamous cell carcinoma 
[32].  Fluorescein was the contrast agent 
used to acquire these images. The 
variations in tissue architecture between 
the different sites can be clearly 
visualized.  
Several studies have compared the performance of confocal microendoscopy to HD-WLE 
examination and narrow-band imaging in the esophagus and colon. Sharma et al. assessed the 
sensitivity and specificity of pCLE in conjunction with HD-WLE compared to HD-WLE alone 
in a prospective, randomized, multi-center trial including 101 patients with BE.  Images were 
acquired in fluorescence mode with fluorescein (2.5 mL, 10%) as the contrast agent. After each 
site was imaged with pCLE, a biopsy was taken at the same location for histopatholgical 
assessment.  The sensitivity and specificity were reported to be 34.2% and 92.7% respectively 
for HD-WLE alone and 68.3% and 87.8% for HD-WLE with pCLE.  Out of the 120 sites 
Figure 3.  pCLE imaging of normal squamous epithelium 
in  the  esophagus  (A),  BE without  dyslplasia  (B),  high‐
grade  dysplasia  (C),  and  carcinoma  (D).  (Shahid  MW 
and Wallace MB.  Endoscopic Imaging for the Detection 
of  Esophageal Dysplasia  and  Carcinoma.   Gastrointest 
Endosc Clin N Am 2010;20:11‐24; with permission) 
diagnosed with high grade dysplasia or early carcinoma, HD-WLE alone missed 79 sites while 
the addition of pCLE reduced the number of missed sites to 38 [26].  
Wang et al. also employed pCLE to image the colon in vivo in a study of 54 patients. 
Fluorescence images were acquired following the administration of fluorescein.  After imaging, a 
pinch biopsy was also acquired at each site for histopathology.  Image analysis was performed in 
this study to distinguish between normal mucosa, hyperplasia, tubular adenoma, and villous 
adenoma.  Analysis of each image consisted of calculating the fluorescence contrast ratio which 
was defined as the ratio of the mean intensity of the lamina propria to the mean intensity of a 
crypt in a selected region of interest.  Using the fluorescence contrast ratio, the study 
documented a sensitivity and specificity of 91% and 87%, respectively, when distinguishing 
between normal and lesional mucosa (including hyperplasia and adenomatous lesions). In 
addition, high sensitivities and specificities were found when distinguishing hyperplasia from 
adenoma (97% and 96%) and tubular adenoma from villous adenoma (100% and 92%) [31]. 
Another use for high-resolution imaging is detecting neoplasia after therapy.  Endoscopic 
mucosal resection (EMR) is generally considered appropriate for flat neoplastic lesions less than 
1.5 cm in size that can be easily accessed by the endoscope [33].  High resolution imaging 
techniques can be useful in determining the perimeters for EMR, ensuring that all neoplastic 
areas have been removed.  Shahid et al. evaluated the diagnostic accuracy of pCLE in detecting 
residual colorectal neoplasia after EMR in a prospective blind study of 92 patients.  The goal was 
to compare pCLE to chromoendoscopy techniques such as NBI and to assess the diagnostic 
accuracy of the two modalities used together.  Fluorescein was used as a contrast agent when 
performing pCLE.  In the study, 92 patients had EMR’s performed on a total of 129 sites.  The 
EMR scars were imaged at all 129 sites.  Histology determined that 29 sites had residual 
neoplasia.  NBI was able to identify the residual neoplasias with a sensitivity and specificity of 
72% and 78%, respectively while pCLE was reported to have sensitivity and specificity of 97% 
and 77%. When the two modalities were combined, a sensitivity and specificity of 100% and 
87% was reported [25].  
High-resolution microendoscopy (HRME) is another fiber bundle based confocal 
technology that offers a portable, low-cost alternative to traditional confocal microendoscopy 
[34, 35]. Similar to pCLE, HRME acquires images by placing the fiber bundle in direct contact 
with the tissue surface.  Instead of scanning through each optical fiber as with pCLE, each fiber 
in the bundle acts as an individual pixel which collectively forms a high resolution image that is 
comparable with other confocal microendoscopy techniques. HRME has been evaluated for use 
in a few studies for the GI tract [34, 35].  Additionally, it has been evaluated in a preliminary 
study in northern China. In this study, the performance of HRME was compared to the 
performance of chromoendoscopy using Lugol’s iodine. Preliminary results have shown that 
even novice users can be trained to differentiate between normal, dysplastic, and neoplastic 
tissues with the HRME   (http://www.youtube.com/watch?v=eJi28REXN_M). 
 
Preclinical Development 
In the preclinical setting, many groups are working to develop new contrast agents, 
including both vital dyes and molecular-targeted agents, to enhance widefield and high 
resolution imaging.  Also, as imaging techniques have matured, there has been an increased 
focus on the co-registration of widefield molecular imaging and high resolution imaging.  Some 
recent developments are highlighted below. 
Widefield Imaging 
 While proflavine, a vital dye, has been primarily used clinically as a contrast agent to 
assist in high resolution imaging studies, Thekkek et al. recently demonstrated proflavine for use 
in widefield fluorescence imaging.  Proflavine was applied to resected specimens from patients 
who underwent an EMR, esophagectomy, or colectomy.  The contrast agent enhanced 
visualization of glandular structure in widefield fluorescence images, including glandular 
distortion and effacement in Barrett’s-associated neoplasia, as well as irregularly spaced colonic 
crypts associated with colonic dysplasia during fluorescence imaging [21].  
Bird-Lieberman et al. studied the use of lectins as a molecular-targeted agent to identify 
progression of Barrett’s esophagus to carcinoma ex vivo.  They examined gene expression 
profiling data from samples at various stages of progression and determined that upregulation of 
cell-surface glycan degradation pathways corresponded with progression from Barrett’s to EAC.  
Accordingly, lectins such as wheat germ agglutinin (WGA), helix pomatia agglutinin (HPA), and 
aspergillusoryzae lectin (AOL) all exhibited reductions in binding to the human esophagus 
during EAC progression.  Histochemical analysis subsequently showed that WGA and AOL had 
the most significant reduction in binding with progression of Barrett’s to EAC.  WGA was 
chosen for further study as a molecular probe due to its common presence in human diets.  WGA 
labeled with fluorescein was applied to resected esophagi ex vivo and imaged using widefield 
techniques.  Both white light imaging and AFI performed without the WGA-fluorescein contrast 
agent identified no abnormalities.  However, after the application of WGA areas of reduced 
fluorescence were observed correlating to areas of reduced WGA binding and dysplasia, as 
shown in Figure 4.  The WGA contrast agent was able identify areas of dysplasia that would 
have otherwise been missed with normal WLE and AFI [36].   
Figure  4.  Whole‐organ  imaging  ex 
vivo.(a)  White‐light  (left), 
fluorescence  at  490–560  nm  prior  to 
the  application  of  WGA  (middle), 
fluorescence  at  490–560  nm  after 
application  of  WGA  and  Alexa  Fluor 
488 (right).  Areas of low WGA binding 
appear  in  purple  and  high  binding  in 
green.    The  dashed  white  line  is  to 
facilitate orientation between images.  
(b) Grid  showing pathological map of 
the  resected  specimen.    The  black 
dashed  line  in  b  represents  the 
longitudinal  axis  shown  in  a.  (c)  The 
same specimen opened  longitudinally 
with  grid  overlay  from  b.  (d) 
Esophagus specimen  imaged using an 
IVIS  200  camera  which  quantified 
fluorescence by color coded map.  The 
pink  arrow marks  an  area  of  artifact 
from  the  exposed  submucosal  tissue, 
and  the blue arrow  indicates  the  site 
of  a  previous  endoscopic  mucosal 
resection (outlined with a dashed gray box).  (e) Histology from various grid locations. (Bird‐Lieberman EL, 
Neves  AA,  Lao‐Sirieix  P,  et  al.    Molecular  imaging  using  fluorescent  lectins  permits  rapid  endoscopic 
identification of dysplasia in Barrett’s esophagus.  Nat Med 2012;18:315‐21; with permission) 
In an in vivo CPC;Apc mouse model study Miller et al. developed a fiber optic 
multispectral scanning endoscope designed to image multiple molecular targets simultaneously 
for use in early diagnosis of colorectal cancer.  They identified three peptides (KCCFPAQ, 
AKPGYLS, LTTHYKL) that exhibited specific binding to colorectal adenomas and labeled them 
using fluorescence labels with minimal spectral overlap.  Images acquired with the multispectral 
endoscope could be used to differentiate the emission spectra of two of these labels successfully, 
enabling simultaneous imaging of two molecular probes in vivo.  Spatially distinguishable 
binding patterns were apparent during imaging, suggesting different binding targets for the 
peptides in dysplastic tissue.  However, the author indicates that further study into 
distinguishable dyes for molecular agents and algorithms to account for variations in tissue 
morphology and orientation are needed [37].   
 
High resolution imaging: increasing accuracy 
One of the key limitations of high resolution imaging is the limited field of view.  
Consequently, high resolution techniques sample only a small fraction of the mucosal surface at 
risk, presenting challenges especially in heterogeneous regions of tissue.  Two techniques have 
been evaluated to overcome this limitation.  One option is to couple the use of high resolution 
imaging with a widefield imaging system, employing the widefield system first to identify areas 
of suspicion, which can then be characterized by a high resolution system.  Another technique 
recently developed is video mosaicing, in which consecutive video frames acquired with a high 
resolution system are stitched together as the probe is advanced along the tissue.  This is can be 
especially useful for visualizing the extent of a lesion and giving a broader sense of the overall 
tissue morphology.  Video mosaicing can allow a clinician to acquire high resolution images 
from areas approximately 2 – 30x larger than one single field of view [38,39].  While video 
mosaicing is a promising approach, current publications have only demonstrated its use in post-
processing.   
There has also been a focus on developing targeted contrast agents to be used with high 
resolution imaging. Goetz et al. used fluorescently labeled EGFR antibodies as a contrast agent 
for detection of colorectal cancer.  Confocal laser endomicroscopy images were acquired from 
mice in vivo (n = 68) in addition to ex vivo specimens of human colorectal mucosa.  Tumors in 
the mice were established using human colorectal cancer cell lines with high (SW480) or low 
(SW620) expression of EGFR. In the rodent model, the confocal probe was scanned across the 
surface of the tumor to acquire fluorescence images. The tumors were also processed for 
histology and immunohistochemistry.  Images acquired from the mice in vivo were graded on a 
0-3+ scale by two independent investigators according to fluorescence intensity of each image.  
Mice with a tumor containing the SW480 line were found to have significantly higher mean 
fluorescence intensity (1.92 ± 0.22) than mice with SW620 tumors (0.59 ± 0.21). The resected, 
ex vivo human colorectal mucosa specimens were incubated with antibody solution and also 
imaged.  There was a statistically significant difference in the mean fluorescence intensity for 
neoplasia (2.13 ± 0.30) and normal mucosa (0.25 ± 0.16) [29].   
In an in vivo human trial, Hsiung et al. has demonstrated the use of a specific contrast 
agent that targets colonic dysplasia with pCLE.  The contrast agent used was a fluorescently 
labeled heptapeptide sequence which was determined to specifically bind to areas of colonic 
dysplasia.  In this study, polyps were first endoscopically identified.  Following identification, 
the peptide was applied and then imaged with pCLE.  A neighboring, normal region of mucosa 
was also imaged.  Polyps imaged with pCLE were then biopsied and processed for histology.  
Characteristic fluorescence images of the colon are displayed in Figure 5.  As can be seen, the 
contrast agent primarily binds to the dysplastic crypts, while the normal crypts are unlabeled.  A 
total of 18 polyps were imaged with 5 representative images selected for each polyp.  Analysis of 
the acquired images consisted of comparison of the mean fluorescence intensity between normal 
mucosa and the adenoma in three 25 x 25 µm regions of interest for each image acquired, 
yielding a total of 270 different regions of interest.  This resulted in a sensitivity and specificity 
of 81% and 82%, respectively, when comparing the mean fluorescence intensity between normal 
tissue and adenomas [40].   
Figure  5.    In  vivo  confocal  fluorescence 
images  of  the  border  between  colonic 
adenoma  and  normal  mucosa,  showing 
peptide binding to dysplastic epithelial cells. 
The  endoscopic  view  (A),  border  (B), 
dysplastic crypt (C) and adjacent mucosa (D) 
are shown with scale bars of 20μm.  (Hsiung 
PL, Hardy J, Friedland S, et al.   Detection of 
colonic  dysplasia  in  vivo  using  a  targeted 
heptapeptide and confocal microendoscopy.  
Nat Med 2008;14:454‐8; with permission) 
 
Interferometric Techniques 
Various interferometric techniques have been developed to yield morphological 
information about the tissue.  The light scattered from tissue can be interfered with a reference 
beam, providing information about the structure of the tissue.  Illumination with a source 
characterized by a low coherence length, a technique known as time domain low coherence 
interferometry (LCI), can be used to selectively process light scattered from varying depths in 
the tissue by changing the distance travelled by the reference arm [41,42].  By sweeping the 
wavelength of the light source, rather than modifying the distance travelled by the reference 
beam, Frequency Domain LCI demonstrates further improvements in SNR and an increase in 
data acquisition time [41,43,44].  Furthermore, the angle at which the light is incident on the 
tissue can be varied using a technique called angle resolved LCI (a/LCI), yielding information 
about the angular intensity distribution of the scattered light as a function of depth [45-47].  The 
detected light can then be processed to yield information about the mean size and relative 
refractive index of cell nuclei in the tissue.   
Optical coherence tomography (OCT) is an imaging interferometric technique that 
obtains multiple LCI scans, yielding 3-D images with micrometer resolution that provide 
detailed morphologic information about the tissue.  While OCT has become a clinical resource in 
ophthalmology, endoscopic OCT has been demonstrated in vivo in the GI tract to provide high 
resolution images of the esophagus [48].  Recent work has investigated combining the 
biochemical information gained from molecular imaging with the high resolution images 
obtained from interferometric techniques like OCT.  Yuan et al combined fluorescence 
molecular imaging (FMI) with OCT using a dichroic to simultaneously illuminate the tissue with 
a different wavelength for each modality [49].  Excised small and large bowels (N=4) of male 
C57BL/6J APCMin/+ mice were imaged, and fluorescence was obtained using UEA-1 
conjugated contrast agent, which has been shown to bind to the surfaces of adenomatous polyps 
due to the over expression of the carbohydrate α-L-fucose on the surface of the polyps.  
Backscattered and fluorescent light were captured allowing the scattering coefficient and 
fluorescence intensity of the tissue to be measured simultaneously.  In Figure 6A, an OCT image 
where the tissue surface height is color coded reveals four hot spots, indicating the presence of 
four raised polyps.  Cross sectional OCT images and histology for the lines in Figure 6A are 
displayed in Figures 6B-6E and 6F-6I, respectively.  The raised polyps are easily distinguished 
from the surrounding tissue.  The tissue scattering coefficient and fluorescence image are 
displayed in Figure 6J and 6K, and are fused in Figure 6L, showing that the polyps exhibit higher 
scattering coefficients and fluorescence intensities than the surrounding tissue.   
In other work, Iftimia et al. demonstrated co-registered ex vivo widefield fluorescence 
imaging and OCT using colon tissue from ApcMin mice [50].  Fluorescence imaging was 
achieved using poly(epsilon-caprolactone) microparticles labeled with a NIR dye and 
functionalized with an RGD (argenine-glycine-aspartic acid) peptide to recognize the over 
expression of ανβ3 integrin receptor (ABIR).  Winkler et al. combined OCT and fluorescence 
microscopy in vivo via endoscope using the azoxymethane-treated mouse model of colon cancer 
[51].  Fluorescence was achieved using the conjugation of a near-infrared fluorescent dye, Cy5.5, 
to single chain vascular endothelial growth factor.  The combination of OCT and spectroscopy 
has also been investigated by Robles et al., who demonstrated the combination of both 
techniques using a source in the visible domain [52].  
 
Figure 6.  Co‐registered OCT/FMI imaging of intestinal polyps incubated with UEA‐1 conjugated liposomes 
ex vivo. (A) OCT en face surface image. Tissue surface height is color‐coded (ranging from 1 – 2.5 mm). Four 
polyps are clearly visible as elevated tissue surface height. (B‐I) Cross‐sectional OCT images corresponding 
to the horizontal lines 1‐4 in A. Polyps (P) are visible as protruded masses in B, D, and H. Normal mucosa is 
shown in F. The scale bars in B‐H are physical distance and a refractive index of 1.4 for tissue was used for 
calculating  the physical distance.   Corresponding histology  (C, E, G,  I) confirm  the OCT  images.  (J) Tissue 
scattering coefficient (μs)  image ranges from 100‐200 cm‐1. Polyps show higher extinction coefficients. (K) 
Fluorescence  image  using  the  UEA‐1  conjugated  contrast  agents.  Fluorescence  intensities  are  higher 
around polyp areas than the surrounding mucosa. (L) Fused scattering coefficient and fluorescence image 
with a scale bar of 1 mm. (Yuan S, Roney CA, Wierwille J, et al.  Combining Optical Coherence Tomography 
with  Fluorescence Molecular  Imaging:  Towards  Simultaneous Morphology  and Molecular  Imaging.  Phys 
Med Biol 2010;55:191–206; with permission.) 
 Conclusion 
The need to improve the detection and classification of early stage neoplasia in the 
esophagus and colon has led to the development of a variety of widefield and high resolution 
optical imaging techniques.  While some widefield techniques, such as AFI and NBI, do not 
require the application of contrast agents, these techniques and others could potentially be 
enhanced by the use of contrast agents that specifically highlight biochemical changes associated 
with neoplasia.  Widefield fluorescence and high resolution imaging such as confocal laser 
endomicroscopy and OCT can combine molecular and morphological imaging to yield 
information about the structure and nature of the tissue.  Of specific note are the recent 
advancements in targeted contrast agents, which have been used to highlight areas of dysplasia.     
While promising, there are a number of challenges that must be solved before large scale 
implementation of optical molecular imaging can be achieved.  First, larger scale, multi-central 
studies are required with appropriate histologic endpoints to properly assess the diagnostic 
potential of each modality.  In cases where commercial instruments are not yet available, 
additional effort is required to ensure standardization of imaging platforms.  In the longer term, 
further study is required to examine whether the use of new modalities has a positive impact on 
patient outcomes.  There are additional barriers to the implementation of approaches that rely on 
targeted contrast agents, including the identification of biomarkers which are sufficiently and 
consistently upregulated  in neoplasia, the development of appropriate delivery formulations, and 
navigation of complex regulatory barriers.   
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